In the case of CRC cells, it seems that the inhibition of GSH-GPX4 and CoQ-FSP1 axes should be coupled with other metabolic modulators, such as inhibitors of glycolysis/Warburg effect. This evidence concerns the gene AIFM2 and colorectal carcinoma.